Bioassay

Viva Biotech's Recent Conferences & Events Review

Retrieved on: 
Friday, May 5, 2023
Molecule, Dai, GMP, Communication, SAPA, Senior, ASMS, Marketing, Development, Journal, Patient, Environment, EHS, Science, Friends, Synthesis, Attention, Production, A39, CDE, Drug discovery, PCSK9, CIO, FDA, Conference, NMPA, BD, D, Medicinal chemistry, PROTAC, Intellectual property, AACR, Exhibition, SPR, Challenge, API, Parlour, American Association for Cancer Research, PDT, Biomedicine, Forum, Synthetic biology, Factorization of polynomials, Drug development, MOA, CMC, Booth, NDA, EDT, CDMO, Estate (law), Artificial intelligence, Fine chemical, Pharmaceutical industry, Medical device, Bioassay, IND

Experts shared a lot of great contents and idea in these conferences and events.

Key Points: 
  • Experts shared a lot of great contents and idea in these conferences and events.
  • As one of the key players in innovative drug discovery CRO, Viva has served thousands of global innovative drug development clients in the past decade.
  • He believes that in the future, Viva Biotech can empower more domestic innovative drug companies and help them achieve internationalization in original drug research.
  • Viva would continue to strengthen one-stop drug development and manufacturing service platform to better empower the development of biopharmaceutical innovation.

Numinus Expands Natural Psychedelic Research with New Biosecurity License

Retrieved on: 
Monday, March 14, 2022
Human body, Industry, Health Canada, Trauma, Company, General manager, Research, Therapy, List of cosmic entities in Marvel Comics, Public Health Agency of Canada, Pharmacokinetics, Public Health Agency, Depression, Pain, Multimedia, Suretrack Contracts Services, Drug prohibition law, Sale, Blood, TSX, Anxiety, Containment, PK, CL2, CEO, Forward-looking statement, Psilocybin, View, Orbitrap, Pharmaceutical industry, Bioassay, Psilocybe, BC

The addition will contribute novel data on natural psychedelics, presenting additional IP opportunities and another revenue driver through contract research services.

Key Points: 
  • The addition will contribute novel data on natural psychedelics, presenting additional IP opportunities and another revenue driver through contract research services.
  • The license is in addition to Numinus Bioscience's existing Controlled Drugs and Substances Dealer's License from Health Canada and underscores Numinus' long-term strategy of establishing a center of excellence for natural psychedelic research, including extensive license amendments and investment into state-of-the-art equipment such as the Orbitrap, which identifies metabolites in the body and will play a key role in the PK and pre-clinical studies.
  • "With this new license, Numinus is more committed than ever to advancing psychedelic research from theory to practice," said Payton Nyquvest, CEO and founder, Numinus.
  • The Numinus model including psychedelic production, research and clinic care is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use.

Center for Breakthrough Medicines Launches Analytical Testing Services for Advanced Therapies, Bringing Solutions to a Supply-Constrained Industry

Retrieved on: 
Wednesday, February 16, 2022
Patient, Food, CEO, Food and Drug Administration, CGT, Center, Review, Solution, Vaccine, International Council, Molecular biology, IND, Process, NGS, GMP, Safety, Philosophy, Method, Plasmid, FDA, View, Education, Communities and Justice Directorates, CDMO, Laboratory, Senior, CBM, ICH, Multimedia, DNA, Industry, Bioassay, Heart, Fine chemical, Maintenance (technical), Pharmaceutical industry, Online shopping

KING OF PRUSSIA, Pa., Feb. 16, 2022 /PRNewswire/ -- The Center for Breakthrough Medicines (CBM) announced the opening of their analytical testing services laboratories that will deliver the most comprehensive testing capabilities in the industry.

Key Points: 
  • KING OF PRUSSIA, Pa., Feb. 16, 2022 /PRNewswire/ -- The Center for Breakthrough Medicines (CBM) announced the opening of their analytical testing services laboratories that will deliver the most comprehensive testing capabilities in the industry.
  • "Our laboratories support R&D and GMP testing services, enabling the continued expansion of the on-site capabilities that can be scaled up at our expansive King of Prussia facility," said Dana Cipriano, Senior Vice President of Testing and Analytical Services, Center for Breakthrough Medicines.
  • "CBM's Testing and Analytical Services business has a concentrated focus on meeting the unprecedented market demand where testing queues are at all-time highs," said Joerg Ahlgrimm, President and CEO, Center for Breakthrough Medicines.
  • CBM's Testing and Analytical Services strengthen the company as a leading contract testing business, making testing a key strategic asset supporting the contract development and manufacturing organization (CDMO), and helps fill an extensive and growing analytical testing shortage in the CGT industry.

Magenta Therapeutics Announces Update on U.S. FDA Investigational New Drug Application for MGTA-117 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

Retrieved on: 
Wednesday, July 21, 2021
Stem cells, Biotechnology, Pharmaceutical, Oncology, Health, FDA, Genetics, Clinical trials, Natural sciences, Physical sciences, Chemistry, Aquatic ecology, Bioassay, Environmental science, Pharmacology, Water pollution, Food and Drug Administration, Toxicology, Assay, MGTA-117, Magenta Therapeutics, MGTA-117, MAGENTA THERAPEUTICS

This was the only clinical hold item identified by the FDA and does not relate to the toxicology or manufacturing of MGTA-117.

Key Points: 
  • This was the only clinical hold item identified by the FDA and does not relate to the toxicology or manufacturing of MGTA-117.
  • Magenta has initiated the development of the bioassay and intends to work closely with the FDA to determine the application of the bioassay for dose escalation.
  • We are actively developing the bioassay requested by the FDA and do not expect significant technical challenges in its completion.
  • Magenta undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

Drug Developers Can Measure ADCC in Biologically Relevant Systems with New Promega Bioluminescent Primary Cell Bioassay

Retrieved on: 
Wednesday, March 3, 2021
Research, Pharmaceutical, Oncology, Medical devices, Genetics, Clinical trials, Science, Biotechnology, Medical Supplies, FDA, Other Science, Health, Medical specialties, Branches of biology, Immunology, Clinical medicine, Immune system, Antibody-dependent cellular cytotoxicity, Peripheral blood mononuclear cell, ADCC, Promega, Bioassay, Cytotoxicity, Antibody

Drug developers have a new bioluminescent tool to characterize how potential pharmaceuticals behave in biologically relevant systems.

Key Points: 
  • Drug developers have a new bioluminescent tool to characterize how potential pharmaceuticals behave in biologically relevant systems.
  • A new primary cell bioassay from Promega Corporation uses peripheral blood mononuclear cells (PBMCs) to measure the antibody-dependent cellular cytotoxicity (ADCC) of antibodies during drug development and characterization.
  • This platform provides a more consistent and reliable alternative to traditional primary cell ADCC bioassays.
  • View the full release here: https://www.businesswire.com/news/home/20210303005143/en/
    The PBMC ADCC Bioassay is the first kit to offer ADCC-qualified PBMCs alongside Promega technologies.

New England Bioassay Inc. spins out from GZA as new, independent firm

Retrieved on: 
Monday, February 3, 2020
Environment, NEB, Bioassay, Nature, Articles

New England Bioassay Inc. (NEB), a leading provider of ecological and wastewater-toxicity testing, has reached an agreement to spin out from longtime owner GZA GeoEnvironmental Inc. and become an independent company.

Key Points: 
  • New England Bioassay Inc. (NEB), a leading provider of ecological and wastewater-toxicity testing, has reached an agreement to spin out from longtime owner GZA GeoEnvironmental Inc. and become an independent company.
  • All of us at NEB were delighted to reach agreement with GZA on this win-win opportunity for both of our companies, Mrs. Wills said.
  • Going forward, NEB will be known as New England Bioassay Inc., the same name the company used up to its acquisition by GZA in 2010.
  • All current staff will be remaining with the newly independent NEB, continuing to provide the same high-quality customer service clients have come to expect.

Solutions for Assay Automation to be Presented by Catalent Biologics at BEBPA US Bioassay Conference

Retrieved on: 
Tuesday, February 19, 2019
Natural sciences, Physical sciences, Chemistry, Catalent, Environmental science, Bioassay, Assay

Solutions for Automation of GMP Assays, Including Bioassays".

Key Points: 
  • Solutions for Automation of GMP Assays, Including Bioassays".
  • Dr. Sadick will talk through several strategies employed by Catalent, and will use case studies to demonstrate the benefits of assay automation and explain how challenges were overcome.
  • Dr. Sadick coordinates and oversees bioassay, ELISA and molecular biology projects for Catalent Biologics.
  • Previously, he managed the company's bioassay/relative potency team for 10 years at Catalent Biologics' facility in Kansas City, Missouri.

Assay Automation to be Presented by Catalent Biologics Expert at WCBP Symposium

Retrieved on: 
Thursday, January 17, 2019
Chemistry, Catalent, Bioassay, Assay, Nature

On Tuesday, Jan. 29 at 12:45 p.m., Mike Sadick, Ph.D., Principal Scientist, Catalent Biologics, will present "Automated Solutions for Relative Potency Assays, (GMP and Non-GMP), Now and Future State".

Key Points: 
  • On Tuesday, Jan. 29 at 12:45 p.m., Mike Sadick, Ph.D., Principal Scientist, Catalent Biologics, will present "Automated Solutions for Relative Potency Assays, (GMP and Non-GMP), Now and Future State".
  • In his presentation, Dr. Sadick will use case studies to discuss the benefits of assay automation and discuss Catalent's current automation platforms, as well as exploring the potential future direction of assay automation.
  • Dr. Sadick coordinates and oversees bioassay, ELISA and molecular biology projects for Catalent Biologics.
  • Previously, he managed the company's bioassay/relative potency team for 10 years at Catalent Biologics' facility in Kansas City, Missouri.